Top

15-02-2025 | Chronic Inflammatory Bowel Disease | Narrative review

Anemia in inflammatory bowel disease—A comprehensive review

Authors: Amit Kumar Dutta, Hemanth Chinthala, John Titus George, David Mathew Thomas, Anjilivelil Joseph Joseph

Published in: Indian Journal of Gastroenterology

Abstract

Anemia is a frequent complication in inflammatory bowel disease (IBD) patients. The etiology is multifactorial, with iron deficiency and anemia of chronic disease being the main reasons. Other causes include vitamin B₁₂ and folate deficiency, hemolytic anemia and medications such as azathioprine and sulfasalazine. Apart from physical symptoms, it is associated with several negative outcomes, including poor quality of life, increased risk of hospital admission, increased risk of surgery and higher treatment costs. Diagnostic evaluation aims to identify the underlying cause and severity to determine the appropriate therapeutic strategy. Investigations include a complete blood count, iron indices, inflammatory markers and vitamin B₁₂ and folate levels. Patients with iron deficiency need adequate replacement therapy to improve hemoglobin and replenish iron stores. Those with moderate to severe anemia and/or active disease need intravenous iron, while mild anemia can be treated with oral iron. Multiple parenteral iron formulations are available which differ in dose and frequency of administration. Traditional oral iron supplements are available in ferrous forms, which, although effective, are associated with gastrointestinal side effects. Newer oral iron formulations have helped reduce these adverse effects but are expensive. Anemia of chronic disease is mainly driven by the effects of inflammatory mediators on iron metabolism and erythropoiesis and treatment requires control of disease activity. Relapse of anemia after therapy is frequent; hence, patients need to be closely followed up for early detection and appropriate management. Significant advances have been made in understanding the pathophysiology of anemia in IBD and better and safer iron formulations are available. However, a significant proportion of IBD patients with anemia go undetected or untreated and there is a need for improved recognition and better management practices. This review discusses various aspects of anemia in IBD and the current approach to diagnosis and management.

Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18:1–37. https://doi.org/10.1093/ecco-jcc/jjad108.

Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53:1190–7. https://doi.org/10.1136/gut.2003.035758.

Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014;20:936–45. https://doi.org/10.1097/01.MIB.0000442728.74340.fd.

Chaubal A, Pandey V, Choksi D, et al. Anemia in patients with ulcerative colitis in remission: a study from western India. Indian J Gastroenterol. 2017;36:361–5. https://doi.org/10.1007/s12664-017-0791-z.

Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123–30. https://doi.org/10.1097/01.MIB.0000196646.64615.db.

Ghoneima AS, Flashman K, Dawe V, Baldwin E, Celentano V. High risk of septic complications following surgery for Crohn’s disease in patients with preoperative anaemia, hypoalbuminemia and high CRP. Int J Colorectal Dis. 2019;34:2185–8. https://doi.org/10.1007/s00384-019-03427-7.

Blaney H, Vu P, Mathew A, et al. Anemia severity associated with increased healthcare utilization and costs in inflammatory bowel disease. Dig Dis Sci. 2021;66:2555–63. https://doi.org/10.1007/s10620-020-06590-y.

Kang EA, Chun J, Im JP, et al. Anemia is associated with the risk of Crohn’s disease, not ulcerative colitis: a nationwide population-based cohort study. PLoS One. 2020;15: e0238244. https://doi.org/10.1371/journal.pone.0238244.

Bergamaschi G, Castiglione F, D’Incà R, et al. Prevalence, pathogenesis and management of anemia in inflammatory bowel disease: an IG-IBD multicenter, prospective, and observational study. Inflamm Bowel Dis. 2023;29:76–84. https://doi.org/10.1093/ibd/izac054.

10.

Patel D, Yang YX, Trivedi C, et al. Incidence, duration, and management of anemia: a nationwide comparison between IBD and non-IBD populations. Inflamm Bowel Dis. 2020;26:934–40. https://doi.org/10.1093/ibd/izz206.

11.

Peyrin-Biroulet L, Bouguen G, Laharie D, et al. Iron deficiency in patients with inflammatory bowel diseases: a prospective multicenter cross-sectional study. Dig Dis Sci. 2022;67:5637–46. https://doi.org/10.1007/s10620-022-07474-z.

12.

Antunes CV, Hallack Neto AE, Nascimento CR, et al. Anemia in inflammatory bowel disease outpatients: prevalence, risk factors, and etiology. Biomed Res Int. 2015;2015:728925. https://doi.org/10.1155/2015/728925.

13.

Burisch J, Vegh Z, Katsanos KH, et al. Occurrence of anaemia in the first year of inflammatory bowel disease in a european population-based inception cohort-an ECCO-EpiCom study. J Crohns Colitis. 2017;11:1213–22. https://doi.org/10.1093/ecco-jcc/jjx077.

14.

Atuğ Ö, Kani HT, Banzragch M, İmeryüz N, Akın H. Incidence rate of anemia in inflammatory bowel diseases. Turk J Gastroenterol. 2016;27:143–8. https://doi.org/10.5152/tjg.2016.16011.

15.

Bengi G, Keyvan H, Durmaz SB, Akpınar H. Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease. World J Gastroenterol. 2018;24:4186–96. https://doi.org/10.3748/wjg.v24.i36.4186.

16.

Al Khoury A, Singh K, Kurti Z, et al. The burden of anemia remains significant over time in patients with inflammatory bowel diseases at a tertiary referral center. J Gastrointestin Liver Dis. 2020;29:555–9. https://doi.org/10.15403/jgld-2705.

17.

Madanchi M, Fagagnini S, Fournier N, et al. The relevance of vitamin and iron deficiency in patients with inflammatory bowel diseases in patients of the Swiss IBD Cohort. Inflamm Bowel Dis. 2018;24:1768–79. https://doi.org/10.1093/ibd/izy054.

18.

Portela F, Lago P, Cotter J, et al. Anaemia in patients with inflammatory bowel disease - a nationwide cross-sectional study. Digestion. 2016;93:214–20. https://doi.org/10.1159/000443927.

19.

Sachan A, Thungapathra M, Kaur H, et al. Comprehensive assessment of nutritional and functional status of patients with ulcerative colitis and their impact on quality of life. Indian J Gastroenterol. 2024;43:254–63. https://doi.org/10.1007/s12664-024-01539-9.

20.

Eriksson C, Henriksson I, Brus O, et al. Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study. Aliment Pharmacol Ther. 2018;48:638–45. https://doi.org/10.1111/apt.14920.

21.

Høivik ML, Reinisch W, Cvancarova M, Moum B. Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Aliment Pharmacol Ther. 2014;39:69–76. https://doi.org/10.1111/apt.12541.

22.

Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:513–9. https://doi.org/10.1002/ibd.21740.

23.

Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95:199–205. https://doi.org/10.3324/haematol.2009.009985.

24.

Nielsen OH, Soendergaard C, Vikner ME, Weiss G. Rational management of iron-deficiency anaemia in inflammatory bowel disease. Nutrients. 2018;10:82. https://doi.org/10.3390/nu10010082.

25.

Kumar A, Sharma E, Marley A, Samaan MA, Brookes MJ. Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterol. 2022;9:e000759. https://doi.org/10.1136/bmjgast-2021-000759.

26.

Oldenburg B, Koningsberger JC, Van Berge Henegouwen GP, Van Asbeck BS, Marx JJ. Iron and inflammatory bowel disease. Aliment Pharmacol Ther. 2001;15:429–38. https://doi.org/10.1046/j.1365-2036.2001.00930.x.

27.

Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347–60. https://doi.org/10.1146/annurev-med-050109-142444.CrossRefPubMed

28.

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–23. https://doi.org/10.1056/NEJMra041809.

29.

Karaskova E, Pospisilova D, Velganova-Veghova M, et al. Importance of hepcidin in the etiopathogenesis of anemia in inflammatory bowel disease. Dig Dis Sci. 2021;66:3263–9. https://doi.org/10.1007/s10620-020-06652-1.

30.

Mucke V, Mucke MM, Raine T, Bettenworth D. Diagnosis and treatment of anemia in patients with inflammatory bowel disease. Ann Gastroenterol. 2017;30:15–22. https://doi.org/10.20524/aog.2016.0083.

31.

Bergamaschi G, Di Sabatino A, Albertini R, et al. Serum hepcidin in inflammatory bowel diseases: biological and clinical significance. Inflamm Bowel Dis. 2013;19:2166–72. https://doi.org/10.1097/MIB.0b013e31829a6e43.

32.

Yueying C, Yu Fan W, Jun S. Anemia and iron deficiency in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2020;14:155–62. https://doi.org/10.1080/17474124.2020.1732817.

33.

Murawska N, Fabisiak A, Fichna J. Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases: pathophysiology, diagnosis, and treatment. Inflamm Bowel Dis. 2016;22:1198–208. https://doi.org/10.1097/mib.0000000000000648.

34.

Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329–42. https://doi.org/10.1038/nri3661.

35.

Huang S, Ma J, Zhu M, Ran Z. Status of serum vitamin B₁₂ and folate in patients with inflammatory bowel disease in China. Intest Res. 2017;15:103–8. https://doi.org/10.5217/ir.2017.15.1.103.

36.

Uzzan M, Galicier L, Gornet JM, et al. Autoimmune cytopenias associated with inflammatory bowel diseases: insights from a multicenter retrospective cohort. Dig Liver Dis. 2017;49:397–404. https://doi.org/10.1016/j.dld.2016.12.006.

37.

Laidlaw ST, Reilly JT. Antilymphocyte globulin for mesalazine-associated aplastic anaemia. Lancet. 1994;343:981–2. https://doi.org/10.1016/s0140-6736(94)90108-2.

38.

Anttila PM, Valimaki M, Pentikainen PJ. Pure-red-cell aplasia associated with sulphasalazine but not 5-aminosalicylic acid. Lancet. 1985;2:1006. https://doi.org/10.1016/s0140-6736(85)90547-1.

39.

Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025–30. https://doi.org/10.1016/s0016-5085(00)70354-4.

40.

Grover N, Bhatia P, Kumar A, et al.TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India. BMC Gastroenterol. 2021;21:327. https://doi.org/10.1186/s12876-021-01900-8.

41.

Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–22. https://doi.org/10.1093/ecco-jcc/jju009.

42.

König P, Jimenez K, Saletu-Zyhlarz G, Mittlböck M, Gasche C. Iron deficiency, depression, and fatigue in inflammatory bowel diseases. Z Gastroenterol. 2020;58:1191–200. https://doi.org/10.1055/a-1283-6832.

43.

Gong SS, Fan YH, Lv B, Zhang MQ, Xu Y, Zhao J. Fatigue in patients with inflammatory bowel disease in Eastern China. World J Gastroenterol. 2021;27:1076–89. https://doi.org/10.3748/wjg.v27.i11.1076.

44.

Bergamaschi G, Castiglione F, D'Inca R, et al. Follow-up evaluation and management of anemia in inflammatory bowel disease: a study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD). Dig Liver Dis. 2024;56:1483–9. https://doi.org/10.1016/j.dld.2024.01.176.

45.

Koutroubakis IE, Ramos-Rivers C, Regueiro M, et al. Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:1760–6. https://doi.org/10.1016/j.cgh.2015.03.029.

46.

Eliadou E, Kini G, Huang J, Champion A, Inns SJ. Intravenous iron replacement improves quality of life in hypoferritinemic inflammatory bowel disease patients with and without anemia. Dig Dis. 2017;35:444–8. https://doi.org/10.1159/000468145.

47.

Herrera-deGuise C, Casellas F, Robles V, Navarro E, Borruel N. Iron deficiency in the absence of anemia impairs the perception of health-related quality of life of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1450–5. https://doi.org/10.1097/MIB.0000000000000768.

48.

Testa A, Rispo A, Romano M, et al. The burden of anaemia in patients with inflammatory bowel diseases. Dig Liver Dis. 2016;48:267–70. https://doi.org/10.1016/j.dld.2015.10.012.

49.

Kumar A, Brookes MJ. Iron therapy in inflammatory bowel disease. Nutrients. 2020;12:3478. . https://doi.org/10.3390/nu12113478.

50.

Bhagya Rao B, Koutroubakis IE, Rivers CR, et al. Correlation of anemia status with worsening bowel damage as measured by Lémann Index in patients with Crohn’s disease. Dig Liver Dis. 2016;48:626–31. https://doi.org/10.1016/j.dld.2016.02.020.

51.

Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva: World Health Organization. 2024 [Internet];[cited 2024 August 5]. Available from: https://www.who.int/publications/i/item/9789240088542.

52.

Oustamanolakis P, Koutroubakis IE, Messaritakis I, Kefalogiannis G, Niniraki M, Kouroumalis EA. Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. J Crohns Colitis. 2011;5:295–300. https://doi.org/10.1016/j.crohns.2011.02.002.

53.

Jimenez KM, Gasche C. Management of iron deficiency anaemia in inflammatory bowel disease. Acta Haematol. 2019;142:30–6. https://doi.org/10.1159/000496728.

54.

Madu AJ, Ughasoro MD. Anaemia of chronic disease: an in-depth review. Med Princ Pract. 2017;26:1–9. https://doi.org/10.1159/000452104.

55.

Dignass A, Farrag K, Stein J. Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions. Int J Chronic Dis. 2018;2018:9394060. https://doi.org/10.1155/2018/9394060.CrossRefPubMedPubMedCentral

56.

Cappellini MD, Comin-Colet J, de Francisco A, et al. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017;92:1068–78. https://doi.org/10.1002/ajh.24820.

57.

Lucendo AJ, Arias Á, Roncero Ó, et al. Anemia at the time of diagnosis of inflammatory bowel disease: prevalence and associated factors in adolescent and adult patients. Dig Liver Dis. 2017;49:405–11. https://doi.org/10.1016/j.dld.2016.12.005.

58.

Camaschella C. Iron deficiency. Blood. 2019;133:30–9. https://doi.org/10.1182/blood-2018-05-815944.

59.

Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86:923–7. https://doi.org/10.1002/ajh.22108.

60.

Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood. 2002;99:1489–91. https://doi.org/10.1182/blood.v99.4.1489.

61.

Syed S, Kugathasan S, Kumar A, et al. Use of reticulocyte hemoglobin content in the assessment of iron deficiency in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64:713–20. https://doi.org/10.1097/MPG.0000000000001335.

62.

Urrechaga E, Hoffmann J, Bernal A, Arévalo JA, Cabriada JL. Reticulocyte hemoglobin content (MCHr) in the assessment of iron deficient erythropoiesis in inflammatory bowel disease. Dig Liver Dis. 2018;50:1178–82. https://doi.org/10.1016/j.dld.2018.04.010.

63.

Aksan A, Farrag K, Stein J. An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2019;13:95–7. https://doi.org/10.1080/17474124.2019.1553618.

64.

Blumenstein I, Dignass A, Vollmer S, Klemm W, Weber-Mangal S, Stein J. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J Crohns Colitis. 2014;8:1308–14. https://doi.org/10.1016/j.crohns.2014.03.010.

65.

Fiorino G, Colombel JF, Katsanos K, et al. Iron therapy supplementation in inflammatory bowel disease patients with iron deficiency anemia: findings from a real-world analysis in Italy. Eur J Gastroenterol Hepatol. 2024;36:563–70. https://doi.org/10.1097/meg.0000000000002740.

66.

Kulnigg-Dabsch S, Schmid W, Howaldt S, et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis. 2013;19:1609–16. https://doi.org/10.1097/MIB.0b013e318281f4db.

67.

Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970;100:301–3.

68.

Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846–53.e1–2. https://doi.org/10.1053/j.gastro.2011.06.005.

69.

Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, et al. Interventions for treating iron deficiency anaemia in inflammatory bowel disease. Cochrane Database Syst Rev. 2021;1:Cd013529. https://doi.org/10.1002/14651858.CD013529.pub2.

70.

Bonovas S, Fiorino G, Allocca M, et al. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95:e2308. https://doi.org/10.1097/md.0000000000002308.

71.

Aksan A, Schoepfer A, Juillerat P, et al. Iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a cost-effectiveness analysis in Switzerland. Adv Ther. 2021;38:660–77. https://doi.org/10.1007/s12325-020-01553-1.

72.

Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis. 2009;15:1485–91. https://doi.org/10.1002/ibd.20925.

73.

Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017;66:863–71. https://doi.org/10.1136/gutjnl-2015-309940.

74.

Mahalhal A, Williams JM, Johnson S, et al. Oral iron exacerbates colitis and influences the intestinal microbiome. PLoS One. 2018;13:e0202460. https://doi.org/10.1371/journal.pone.0202460.

75.

Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther. 2006;24:1507–23. https://doi.org/10.1111/j.1365-2036.2006.03146.x.

76.

Rizvi S, Schoen RE. Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap? Am J Gastroenterol. 2011;106:1872–9. https://doi.org/10.1038/ajg.2011.232.

77.

Pantopoulos K. Oral iron supplementation: new formulations, old questions. Haematologica. 2024;109:2790–801. https://doi.org/10.3324/haematol.2024.284967.

78.

Maas LA, Krishna M, Parian AM. Ironing it all out: a comprehensive review of iron deficiency anemia in inflammatory bowel disease patients. Dig Dis Sci. 2023;68:357–69. https://doi.org/10.1007/s10620-022-07599-1.

79.

de Alvarenga Antunes CV, de Alvarenga Nascimento CR, Campanha da Rocha Ribeiro T, et al. Treatment of iron deficiency anemia with liposomal iron in inflammatory bowel disease: efficacy and impact on quality of life. Int J Clin Pharm. 2020;42:895–902. https://doi.org/10.1007/s11096-020-01044-x.

80.

Howaldt S, Domènech E, Martinez N, Schmidt C, Bokemeyer B. Long-term effectiveness of oral ferric maltol vs intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: a randomized controlled noninferiority trial. Inflamm Bowel Dis. 2022;28:373–84. https://doi.org/10.1093/ibd/izab073.

81.

Bertani L, Tricò D, Zanzi F, et al. Oral sucrosomial iron is as effective as intravenous ferric carboxy-maltose in treating anemia in patients with ulcerative colitis. Nutrients. 2021;13:608. https://doi.org/10.3390/nu13020608.

82.

Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10:e0117383. https://doi.org/10.1371/journal.pone.0117383.

83.

Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877–88. https://doi.org/10.1038/ajg.2013.335.

84.

Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44:838–45. https://doi.org/10.1080/00365520902839667.

85.

Akhuemonkhan E, Parian A, Carson KA, Hutfless S. Adverse reactions after intravenous iron infusion among inflammatory bowel disease patients in the United States, 2010–2014. Inflamm Bowel Dis. 2018;24:1801–7. https://doi.org/10.1093/ibd/izy063.

86.

Detlie TE, Lindstrøm JC, Jahnsen ME, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50:397–406. https://doi.org/10.1111/apt.15386.

87.

Schaefer B, Tobiasch M, Wagner S, et al. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone. 2022;154:116202. https://doi.org/10.1016/j.bone.2021.116202.

88.

Detlie TE, Lindstrøm JC, Jahnsen ME, et al. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: mechanisms and possible clinical impact. World J Gastroenterol. 2021;27:2039–53. https://doi.org/10.3748/wjg.v27.i17.2039.

89.

Aksan A, Işık H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1303–18. https://doi.org/10.1111/apt.14043.

90.

Lucendo AJ, Roncero Ó, Serrano-Duenas MT, et al. Effects of anti-TNF-alpha therapy on hemoglobin levels and anemia in patients with inflammatory bowel disease. Dig Liver Dis. 2020;52:400–7. https://doi.org/10.1016/j.dld.2019.11.019.

91.

Aksan A, Wohlrath M, Iqbal TH, Dignass A, Stein J. Inflammation, but not the underlying disease or its location, predicts oral iron absorption capacity in patients with inflammatory bowel disease. J Crohns Colitis. 2020;14:316–22. https://doi.org/10.1093/ecco-jcc/jjz149.

92.

Syed S, Michalski ES, Tangpricha V, et al. Vitamin D status is associated with hepcidin and hemoglobin concentrations in children with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1650–8. https://doi.org/10.1097/mib.0000000000001178.

93.

El Amrousy D, El-Afify D, Elsawy A, Elsheikh M, Donia A, Nassar M. Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial. Pediatr Res. 2022;92:762–6. https://doi.org/10.1038/s41390-022-02136-2.

94.

Mahadea D, Adamczewska E, Ratajczak AE, et al. Iron deficiency anemia in inflammatory bowel diseases-a narrative review. Nutrients. 2021;13:4008. https://doi.org/10.3390/nu13114008.

95.

Ferreiro-Iglesias R, Barreiro-de-Acosta M, Seijo-Ríos S, Lorenzo A, Domínguez-Muñoz JE. Efficacy of intravenous iron in treating iron deficiency anaemia in patients with inflammatory bowel disease. Are there predictors of response? Rev Esp Enferm Dig. 2011;103:245–9.

96.

Loveikyte R, Duijvestein M, Mujagic Z, Goetgebuer RL, Dijkstra G, van der Meulen-de Jong AE. Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol. BMJ Open. 2024;14:e077511. https://doi.org/10.1136/bmjopen-2023-077511.

97.

Cavallaro F, Duca L, Pisani LF, et al. Anti-TNF-mediated modulation of prohepcidin improves iron availability in inflammatory bowel disease, in an IL-6-mediated fashion. Can J Gastroenterol Hepatol. 2017;2017:6843976. https://doi.org/10.1155/2017/6843976.

98.

Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica. 2010;95:175–8. https://doi.org/10.3324/haematol.2009.017046.

99.

Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–53. https://doi.org/10.1002/ibd.20285.

100.

Katsanos KH, Tatsioni A, Natsi D, Sigounas D, Christodoulou DK, Tsianos EV. Recombinant human erythropoietin in patients with inflammatory bowel disease and refractory anemia: a 15-year single center experience. J Crohns Colitis. 2012;6:56–61. https://doi.org/10.1016/j.crohns.2011.07.004.

101.

Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96:2382–7. https://doi.org/10.1111/j.1572-0241.2001.04094.x.

102.

Hashash JG, Elkins J, Lewis JD, Binion DG. AGA Clinical practice update on diet and nutritional therapies in patients with inflammatory bowel disease: expert review. Gastroenterology. 2024;166:521–32. https://doi.org/10.1053/j.gastro.2023.11.303.

103.

Martin J, Radeke HH, Dignass A, Stein J. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11:19–32. https://doi.org/10.1080/17474124.2017.1263566.

104.

Wiesen A, Wiesen J, Limaye S, Kaushik N. Mesalazine-induced aplastic anemia. Am J Gastroenterol. 2009;104:1063. https://doi.org/10.1038/ajg.2008.164.

105.

Toplicanin A, Toncev L, Matovic Zaric V, Sokic Milutinovic A. Autoimmune hemolytic anemia in inflammatory bowel disease-report of a case and review of the literature. Life (Basel). 2022;12:1764. https://doi.org/10.3390/life12111784.

Title: Anemia in inflammatory bowel disease—A comprehensive review
Authors: Amit Kumar Dutta
Hemanth Chinthala
John Titus George
David Mathew Thomas
Anjilivelil Joseph Joseph
Publication date: 15-02-2025
Publisher: Springer India
Keywords: Chronic Inflammatory Bowel Disease
Anemia
Iron Deficiency Anemia
Anemia Drugs
Ulcerative Colitis
Crohn's Disease
Diagnostics in Gastroenterology
Therapy in Internal Medicine
Published in: Indian Journal of Gastroenterology
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI: https://doi.org/10.1007/s12664-024-01735-7

Podcast | Sexual health in older age

Springer Medicine

Anemia in inflammatory bowel disease—A comprehensive review

Abstract

Podcast | Sexual health in older age

Springer Medicine

Abstract

Please log in to get access to this content